- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00714558
Pharmacokinetics of Fentanyl Following Intravenous and Oral Routes of Administration in Healthy Volunteers
Pharmacokinetics of Fentanyl Citrate Following Intravenous (i.v.) and Oral Routes of Administration in Healthy Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Fentanyl, is an opioid (morphine-like) drug, that has been demonstrated to be an effective pain-killer medication by the i.v. and transdermal (through skin) routes. Fentanyl is used just before, during, and after surgery for its sedative and pain-relieving actions. In addition, fentanyl is currently marketed for transdermal use (Duragesic fentanyl transdermal patch) for the management of chronic pain. The information on the bioavailability of fentanyl solution, following the oral route of administration, is sparse. This is a single-center, randomized (study drug assigned by chance), open-label, 2-treatment, 2-period, crossover study. Healthy volunteers were randomly assigned to 1 of the 2 treatment sequences (AB or BA) with a washout period of 6 to 14 days between treatments. The washout period commenced the day of dosing, after drug administration. Prior to the first treatment period, each healthy volunteer was challenged with naloxone to ensure that he/she was not dependent on morphine-like drugs. A negative naloxone challenge test was required for the healthy volunteer to be eligible for participation in the study. Each healthy volunteer received a 50 mg naltrexone tablet starting 14 hours before dosing and then twice daily ending 24 hours after dosing to block the fentanyl effects. Blood samples were collected, from the arm opposite to the 1 selected for fentanyl i.v administration, for determination of blood fentanyl levels at the scheduled time points. Pulse, blood pressure, breathing rate, body temperature were recorded to monitor the safety. The healthy volunteers were monitored for respiratory depression every 30 minutes during sleep periods. The healthy volunteers remained in the clinic throughout the blood sample collection periods, and were monitored for adverse events throughout the study.
Treatment A: 300 mcg fentanyl citrate administered i.v. over 15 minutes. The 300 mcg (6 mL) i.v. solution was diluted and infused at a rate of 1 mL/minute. Treatment B: 1 mg fentanyl citrate solution administered orally. One mg fentanyl citrate was ingested in 20 mL solution; Naltrexone (50 mg) was administered orally to each healthy volunteer in both periods starting 14 hours before dosing, and twice daily through 24 hours post-dose.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy, non smoker, men and nonpregnant nonlactating women
- Weighing a minimum of 60 kg and were within 15% of ideal weight for height as described in the Metropolitan Life Insurance Height and Weight Standards
- Who did not have a history or show presence of drug or alcohol dependence or abuse
- And who had, after sitting for 5 minutes, blood pressure between the ranges of 100 to 150 mm Hg systolic and 50 to 90 mm Hg diastolic. Any decrease in systolic blood pressure after standing for 2 minutes had to be less than or equal to 20 mm Hg
Exclusion Criteria:
- History of chronic obstructive pulmonary disease or any other lung disease, such as asthma, that would cause carbon dioxide retention
- Known allergy or hypersensitivity to fentanyl or other opioids, naltrexone or naloxone
- Usage of prescription medication (except for birth control medications, sex-hormone replacement or vitamins) within 14 days before Day 1, monoamine oxide inhibitors within 21 days prior to Day 1, over-the-counter medication (except for vitamin supplements or acetaminophen less than 2 gm/day) or herbal medication within 3 days prior to Day 1, alcohol, grapefruit juice, or caffeine within 48 hours before dosing
- Consumption of more than 450 mg of caffeine per day (eg, approximately 5 cups of tea, 3 cups of regular coffee, or 8 cans of cola)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Evaluate the pharmacokinetics of fentanyl citrate following i.v. and oral routes of administration in healthy volunteers, and to assess the absolute bioavailability of fentanyl citrate following oral administration.
|
Secondary Outcome Measures
Outcome Measure |
---|
Assessment of safety. Vital signs, Physical examination, clinical laboratory tests, and electrocardiogram were performed at screening and study termination. Additionally, vital signs were recorded on Days 1 and 2 of both treatment periods.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Analgesics, Opioid
- Narcotics
- Adjuvants, Anesthesia
- Narcotic Antagonists
- Alcohol Deterrents
- Fentanyl
- Naltrexone
- Naloxone
Other Study ID Numbers
- CR003253
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Biological Availability
-
Fundació EurecatCirce, S.L.Not yet recruiting
-
DaacroISTITUTO KURZ ITALIA S.R.L.; Institut Kurz GmbH; Fattoria La Vialla di Gianni...CompletedBiological AvailabilityGermany
-
Wageningen UniversityCompletedBiological Availability
-
Alza Corporation, DE, USACompleted
-
Janssen Infectious Diseases BVBACompletedHealthy | Biological AvailabilityNetherlands
-
Fundació EurecatSilicium Laboratories S.L.; San Antonio Technologies S.L.; Catholic University... and other collaboratorsCompletedBiological Availability | Aluminium OverloadSpain
-
PfizerCompletedBiological AvailabilityUnited States
-
Xspray Pharma ABQPS Bioserve India Pvt LimitedCompleted
-
University of HohenheimUniversidad de Costa RicaCompletedBiological AvailabilityCosta Rica, Germany
-
BayerOrion Corporation, Orion PharmaCompletedBiological AvailabilityGermany
Clinical Trials on Fentanyl citrate; Naltrexone; Naloxone
-
University of California, Los AngelesNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCCompleted
-
University of OsloNorwegian Institute of Public Health; Oslo University Hospital; The Research... and other collaboratorsCompletedOpioid DependenceNorway
-
Alkermes, Inc.Completed
-
INSYS Therapeutics IncCompleted
-
LifespanThe Miriam Hospital; University of Rhode IslandActive, not recruitingOpioid-use DisorderUnited States
-
Paolo MannelliAlkermes, Inc.CompletedLow Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence (BUP/NXT-VIVI)Opiate DependenceUnited States
-
Tanta UniversityCompleted
-
LifespanUniversity of Rhode IslandCompletedOpioid-use DisorderUnited States
-
NYU Langone HealthNational Institute on Drug Abuse (NIDA); The Emmes Company, LLCCompletedOpioid Use DisorderUnited States
-
National Institute on Drug Abuse (NIDA)Completed